Clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4mutation

Timothy A Yap, Afshin Dowlati, Ibiayi Dagogo-Jack, Julien Vibert, Alexander I Spira, Victor Moreno, Salman R Punekar, Emiliano Calvo, Guru P Sonpavde, Mark Awad, Jonathan W Riess, Tatiana Hernández-Guerrero, Benjamin Herzberg, Antoine Italiano, Aurelie Swalduz, Ticiana A Leal, Joseph C Murray, David SP Tan, Patricia LoRusso, Egbert F Smit, Edward B Garon, William Novotny, Robin Guo